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a late-onset monogenetic neurodegenerative disorder, is
caused by a CGG-repeat expansion (55-200) in the 5′
UTR of the fragile-X mental retardation 1 gene (FMR1)
on the X-chromosome [1]. The prevalence of the FMR1
premutation (PM) is about 1:855 in males and 1:291 in
females [2]. Approximately 45.5% of male and 16.5% of
female PM carriers older than 50 years will develop signs
of FXTAS [3]. In addition to the core features of tremor
and gait ataxia, unexplained medical co-morbidities have
been reported, including thyroid disease, cardiac arrhyth-
mias, hypertension, migraine, impotence, and neuropathy
[4]. PM carriers have increased levels of FMR1 mRNA (2
to 8 fold in leucocytes) and normal to slightly reduced
FMR1 protein (FMRP) levels [5]. The current hypothesis
is that FXTAS is caused by an RNA gain-of-function
mechanism. Ubiquitin-positive intranuclear inclusions, are
found in both brain and non-central nervous system
(CNS) organs of patients with FXTAS [6,7]. So far, it is
not clear whether these inclusions are protective or toxic.
Recently, it has been hypothesized that repeat-associated
non-AUG (RAN) translation plays a role in disease
process and inclusion formation. Todd et al. [8] dem-
onstrated that through initiation at a near-ATG codon
located in the 5′UTR of the FMR1 gene a polyGlycine-
containing protein, FMRpolyG, is expressed. This protein
accumulates in ubiquitin-positive inclusions in Drosophila,
cell culture, mouse disease models and brain from FXTAS
patients. To investigate the link between FMRpolyG* Correspondence: r.hukema@erasmusmc.nl
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unless otherwise stated.expression and the co-morbid medical problems associ-
ated with the PM we have developed two novel mouse
monoclonal antibodies against polyGlycine; 8FM and
9FM (for epitopes and specificity see Additional file 1:
Figure S1), and performed immunostaining in CNS as
well as in non-CNS organs of FXTAS patient J.L. (case
6 in [7]; other cases not available). To establish antibody
specificity, we performed immunostaining with both
antibodies on brain sections from FXTAS patient J.L.,
healthy non-demented controls (n = 3) and a patient
with Parkinson disease, Alzheimer disease, or C9FTD.
In hippocampus and cerebellum from FXTAS patient
J.L. we identified FMRpolyG-positive inclusions with
both 8FM (1:10) and 9FM (1:10) antibody (Figure 1a-b,
Additional file 2: Figure S2a-b), as was described previ-
ously [8]. None of the controls showed FMRpolyG-
positive inclusions (data not shown). Next, we studied
the immunolocalization of FMRpolyG protein in heart,
kidney, adrenal gland and thyroid in patient J.L. with
8FM (1:10) and 9FM (1:10), compared to post mortem
non-CNS somatic organ tissues from 3 healthy controls.
We also examined tissues for FMRP (mouse T1A; 1:200)
expression and ubiquitin-positive inclusions (DAKO,
ZO458; 1:200). Consistent with our previous report [7],
ubiquitin-positive intranuclear inclusions were identified
along with a normal distribution of FMRP (data not
shown). Intranuclear FMRpolyG-positive inclusions could
be detected in all organs examined (Figure 1c-h, Additional
file 2: Figure S2c-h). No control tissues showed any
FMRpolyG-positive inclusions (data not shown). Colocali-
zation of ubiquitin- and FMRpolyG-positive inclusions was
visualized and quantified by immunofluorescent double
staining using antibodies against ubiquitin and FMRpolyGLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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Figure 1 9FM FMRpolyG-positive intranuclear inclusions in hippocampus, cerebellum and non-CNS tissues of a FXTAS patient.
FMRpolyG-positive (9FM) intranuclear inclusions in a hippocampus, b cerebellum, c glomeruli and d distal tubule of the kidney, e zona glomerulosa
and f zona reticularis of adrenal gland, g cardiomyocytes and h thyroid. All sections were immunostained with 9FM antibody and counterstained with
hematoxylin. Scale bars represent 50 μm.
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non-CNS organs most inclusions are positive for both
FMRpolyG and ubiquitin, although some rare inclusions
positive for only one of the proteins could also be detected
(Figure 2g, n = 100 inclusions). In conclusion, using twonovel antibodies the present report not only confirms the
existence of FMRpolyG-positive aggregates in CNS tissue
from a FXTAS individual but also demonstrates for the first
time the presence of FMRpolyG-positive intranuclear inclu-
sions in post mortem non-CNS material of a PM carrier
Figure 2 (See legend on next page.)
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Figure 2 Colocalization of FMRpolyG (8FM) and ubiquitin in intranuclear inclusions in hippocampus, cerebellum and of non-CNS
tissues of a FXTAS patient. Staining for ubiquitin (green), FMRpolyG (8FM; red) and DAPI (blue). Colocalization of ubiquitin and FMRpolyG
(yellow) is seen in a hippocampus, b cerebellum, c kidney, d adrenal gland, e cardiomyocytes, and f thyroid; g quantification of inclusions
containing ubiquitin and/or FMRpolyG (n = 100). Scale bars represent 10 μm.
Buijsen et al. Acta Neuropathologica Communications 2014, 2:162 Page 4 of 5
http://www.actaneurocomms.org/content/2/1/162with FXTAS. Furthermore, colocalization of FMRpolyG
and ubiquitin is found in the vast majority of inclusions.
The presence of FMRpolyG-positive intranuclear inclusions
in heart, kidney, adrenal gland and thyroid is consistent
with the unexplained medical co-morbidities reported
in some patients with FXTAS, including thyroid disease,
cardiac arrhythmias, hypertension, migraine, impotence,
and neuropathy. We hypothesize that the underlying
pathological mechanisms of the medical co-morbidities in
systemic tissues share common features (protein toxic
gain-of-function) with CNS pathology of patients with
FXTAS. Our report suggests that in addition to elevated
levels of FMR1 mRNA containing an expanded CGG
repeat, and ubiquitin-positive inclusions, FMRpolyG
expression might also play a role in a toxic gain-of-
function mechanism in medical co-morbidities in
FXTAS (RNA versus FMRpolyG toxic gain-of-function).
Interestingly, a very recent report suggests that RAN
translation products in C9FTD/ALS, toxic dipeptide
repeat proteins (poly-(glycine-arginine) and poly-(pro-
line-arginine)), are toxic in Drosophila [9]. Further
research is needed to understand how FMRpolyG may
elicit toxicity in both CNS and non-CNS organs and its
precise role in co-morbidities in PM carriers. Import-
antly, if FMRpolyG production is important for cellular
toxicity this will open new avenues for therapeutic
intervention studies for FXTAS by developing drugs
that block this aberrant translation.
Additional files
Additional file 1: Figure S1. Epitopes and specificity FMRpolyG
antibodies 8FM and 9FM. a Sequence of the 5′UTR of human FMR1 gene
and the FMRpolyG peptide sequence resulting from RAN translation.
Epitopes of 8FM and 9FM antibodies are boxed. b Monoclonal 8FM and
9FM antibodies were validated on COS7 cells transfected with pEGFP
(Clonetech) plasmid containing the 5′UTR of FMR1 with 5O CGG repeats,
thus expressing the polyGlycine protein fused to GFP. On Western Blot a
specific product could be detected for both antibodies and no product was
detectable in COS7 cells transfected with a control GFP plasmid. c As an
additional control experiment we performed immunostainings for 8FM
antibody and could demonstrate specific intranuclear inclusions in COS7
cells transfected with a construct expressing the FMRpolyG fused to GFP,
while cells tranfected with only GFP did not show any inclusion formation.
Identical results were obtained with 9FM antibody (data not shown).
Additional file 2: Figure S2. 8FM FMRpolyG-positive intranuclear
inclusions in hippocampus, cerebellum and non-CNS tissues of a FXTAS
patient. FMRpolyG-positive (8FM) intranuclear inclusions in a hippocampus,
b cerebellum, c glomeruli and d distal tubule of the kidney, e zona
glomerulosa and f zona reticularis of adrenal gland, g cardiomyocytes
and h thyroid. All sections were immunostained with 8FM antibody
and counterstained with hematoxylin. Scale bars represent 50 μm.Abbreviations
ALS: Amyotrophic lateral sclerosis; C9FTD: Chromosome 9 open reading
frame 72 frontotemporal dementia; CNS: Central nervous system;
FMR1: Fragile-X mental retardation 1; FMRP: Fragile-X mental retardation 1
protein; FXTAS: Fragile X-associated Tremor/Ataxia syndrome; PM: Fragile-X
mental retardation 1 premutation; RAN: Repeat-associated non-AUG.
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